Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios-Reference-Cited by-同舟云学术

Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios

Published:2022-01 Issue:1 Volume:14 Page:
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alz & Dem Diag Ass & Dis Mo

Author:

Bouwman Femke H.¹,Frisoni Giovanni B.²,Johnson Sterling C.³,Chen Xiaochun⁴,Engelborghs Sebastiaan⁵,Ikeuchi Takeshi⁶,Paquet Claire⁷,Ritchie Craig⁸,Bozeat Sasha⁹,Quevenco Frances‐Catherine⁹,Teunissen Charlotte¹⁰^ORCID

Affiliation:

1. Alzheimer Center Amsterdam Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam the Netherlands

2. University of Geneva Geneva Switzerland

3. University of Wisconsin‐Madison, and Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital Madison Wisconsin USA

4. Fujian Medical University Fuzhou China

5. Center for Neurosciences (C4N) Vrije Universiteit Brussel, and Department of Neurology/Brussels Integrated Center for Brain and Memory (Bru‐BRAIN) Universitair Ziekenhuis Brussel, Brussels, and Department of Biomedical Sciences University of Antwerp Antwerp Belgium

6. Niigata University Niigata Japan

7. Université de Paris Cognitive Neurology Center Lariboisière Hospital GHU APHP Nord INSERMU1144 Paris France

8. University of Edinburgh, and Brain Health Scotland Edinburgh UK

9. Roche Diagnostic Solutions Rotkreuz Switzerland

10. Department of Clinical Chemistry Neurochemistry Laboratory Amsterdam Neuroscience Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam the Netherlands

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dad2.12314

Reference50 articles.

1. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

2. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

3. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

4. Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer’s Disease

5. White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status;Journal of Alzheimer's Disease;2024-01-16

2. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease;Scientific Reports;2024-01-05

3. The diamagnetic component map from quantitative susceptibility mapping (QSM) source separation reveals pathological alteration in Alzheimer’s disease-driven neurodegeneration;NeuroImage;2023-10

4. Cellular specificity is key to deciphering epigenetic changes underlying Alzheimer's disease;Neurobiology of Disease;2023-10

5. Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System;Neurology and Therapy;2023-09-25